Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NNC9204-0530 Alone and with Liraglutide in Overweight/Obese Men
NCT02235961Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2014
- Primary completion
- Jul 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC9204-0530 in obesity (2 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment emergent adverse events recorded. Started Sep 2014; status: completed.
02
Drugs
NNC9204-0530
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02235961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02235961.